Outcomes-Based Health Program for Type 2 Diabetes
1 other identifier
interventional
200
1 country
1
Brief Summary
Type 2 diabetes is a growing health concern worldwide, influenced by genetic factors, overweight, metabolic syndrome, and insufficient physical activity. Good treatment and glycemic control can reduce or delay diabetes-related complications, which account for a significant and increasing share of healthcare costs in Finland. Much of this cost growth is due to complications resulting from inadequate diabetes care. Secondary prevention programs can therefore provide both health and economic benefits. Lifestyle interventions are one way to improve type 2 diabetes care and reduce complications. This study aims to evaluate the impact of a digital lifestyle intervention combined with optimized care on treatment and outcomes among adults with type 2 diabetes at high risk for complications. The intervention includes access to the BitHabit "Small Actions" application, which supports healthy lifestyle changes, and for participants with a body mass index (BMI) over 30, the Onnikka weight management application. The study will be conducted in North Savo, Finland, using a case-control design. Approximately 120 participants will receive the intervention and 50-100 will serve as controls. All participants will have their care plans reviewed and updated according to the Finnish Current Care Guidelines for Type 2 Diabetes. Control group participants will receive standard care, while the intervention group will receive standard care plus the digital tools. The study also includes the validation of the PAID (Problem Areas in Diabetes) questionnaire for use in Finland and in the Finnish language. The study duration for each participant is 12 months. Data will be collected through physiological measurements, laboratory tests, questionnaires, and app usage logs. Measurements and questionnaires will be conducted at baseline and after 12 months. The analyses will describe the phenomenon, its prevalence, and associations between variables, as well as potential dependencies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable type-2-diabetes
Started Apr 2025
Typical duration for not_applicable type-2-diabetes
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 10, 2025
CompletedFirst Submitted
Initial submission to the registry
December 22, 2025
CompletedFirst Posted
Study publicly available on registry
January 7, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
January 7, 2026
December 1, 2025
2.6 years
December 22, 2025
December 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (12)
Change from baseline in weight at 12 months
Change from baseline in weight at 12 months. Weight measurement is taken by study nurse both at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Change from baseline in BMI at 12 months
Change from baseline in BMI at 12 months. Weight and height measurement are taken by study nurse both at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Change from baseline in waist circumference at 12 months
Change from baseline in waist circumference at 12 months. Waist circumference is taken by study nurse both at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Change from baseline in Body Roundness Index at 12 months
Change from baseline in Body Roundness Index at 12 months. Weight, height, waist and hip circumference are taken by study nurse both at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Change from baseline in HbA1c at 12 months
Change from baseline in HbA1c at 12 months. HbA1c is a laboratory measurement describing glucose levels, taken both at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Change from baseline in serum lipid levels at 12 months
Change from baseline in serum lipid levels at 12 months. LDL, HDL and triglycerides are laboratory measurements taken both at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Change from baseline in smoking status at 12 months
Change from baseline in smoking status at 12 months. Smoking status is surveyed both at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Change from baseline in physical activity at 12 months
Change from baseline in physical activity at 12 months. Physical activity is surveyed both at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Change from baseline in dietary habits at 12 months
Change from baseline in dietary habits at 12 months. Dietary habits are surveyed both at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Change from baseline in blood pressure at 12 months
Change from baseline in blood pressure at 12 months. Blood pressure measurement is taken by study nurse via Riva Rocci method both at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Self-reported changes from baseline in qualty of life measured by EQ-5D-5L at 12 months
EQ-5D-5L is a standard health questionnaire assessing quality of life across five dimensios: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. EQ-5D-5L questionnaire is filled electronically at baseline and at the end of the study.
From enrollment to the end of follow-up at 12 months
Change from baseline in Problem Areas in Diabetes (PAID) scale at 12 months
PAID scale identifies emotional distress in diabetes, covering issues like worrying complications, goal setting, food, treatment, and social support, common problems including fear, anger, feeling overwhelmed and guilt.
From enrollment to the end of follow-up at 12 months
Study Arms (2)
Digital intervention arm
EXPERIMENTALDigital interventions: BitHabit application and optionally Onnikka application
Control group
NO INTERVENTIONControl group receives same enhancement in treatment plan, but no digital interventions
Interventions
BitHabit digital application for behavioral lifestyle changes
Onnikka weight management digital application
Eligibility Criteria
You may qualify if:
- Type 2 diabetes diagnosed
- At least one of the following:
- diagnosed coronary artery disease,
- diagnosed periferal artery disease,
- diagnosed heart failure,
- diagnosed diabetic renal disease (GFR \<60 OR uACR ≥ 3 for at least three months),
- diagnosed diabetic retinopathy,
- previous stroke,
- diagnosed atrial fibrillation or atrial flutter,
- age ≥ 55 years and at least two of the following conditions:
- smoker
- uses antihypertensive medication or systolic blood pressure \>140 mmHg or diastolic blood pressure \> 80 mmHg,
- uses lipid lowering medication or LDL-cholesterol \> 2.6 or
- BMI \> 25
You may not qualify if:
- eGFR \< 30
- uACR \> 200
- BMI \> 50
- heart ejection fraction EF \< 30
- active cancer or less than five years from cancer treatment at enrollment
- blindness in both eyes
- severe psychotic depression
- inability to utilize digital applications
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kuopio University Hospitallead
- Finnish Diabetes Associationcollaborator
- University of Eastern Finlandcollaborator
Study Sites (1)
Wellbeing services county of North Savo, Nursing and Physician Services
Kuopio, Northern Savonia, Finland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sonja Soininen, MD, PhD
Wellbeing Services County of North Savo, Kuopio, Finland
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Physician in Chief, Teaching clinic Osmo
Study Record Dates
First Submitted
December 22, 2025
First Posted
January 7, 2026
Study Start
April 10, 2025
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
January 7, 2026
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share
Study permission does not allow sharing individual participant data.